223 related articles for article (PubMed ID: 28710351)
21. HPMA-PLGA Based Nanoparticles for Effective In Vitro Delivery of Rifampicin.
Rani S; Gothwal A; Pandey PK; Chauhan DS; Pachouri PK; Gupta UD; Gupta U
Pharm Res; 2018 Dec; 36(1):19. PubMed ID: 30511238
[TBL] [Abstract][Full Text] [Related]
22. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea.
Lee H; Cho SN; Bang HE; Lee JH; Bai GH; Kim SJ; Kim JD
Int J Tuberc Lung Dis; 2000 May; 4(5):441-7. PubMed ID: 10815738
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
24. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.
Lee BY; Clemens DL; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
Nat Commun; 2017 Jan; 8():14183. PubMed ID: 28117835
[TBL] [Abstract][Full Text] [Related]
25. Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update.
Chaiprasert A; Srimuang S; Tingtoy N; Makhao N; Sirirudeeporn P; Tomnongdee N; Theankeaw O; Charoensook S; Leechawengwongs M; Prammananan T
Int J Tuberc Lung Dis; 2014 Aug; 18(8):961-3. PubMed ID: 25199012
[TBL] [Abstract][Full Text] [Related]
26. [Investigation of remaxol efficacy in complex therapy of experimental generalized tuberculosis on mice].
Sukhanova DS; Vinogradova TI; El'kin AV; Zabolotnykh NV; Vasil'eva SN; Vitovskaia ML
Antibiot Khimioter; 2012; 57(1-2):17-22. PubMed ID: 22741197
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.
Li W; Obregón-Henao A; Wallach JB; North EJ; Lee RE; Gonzalez-Juarrero M; Schnappinger D; Jackson M
Antimicrob Agents Chemother; 2016 Sep; 60(9):5198-207. PubMed ID: 27297488
[TBL] [Abstract][Full Text] [Related]
28. Radiometric vs. agar proportion methods for assessing ethionamide resistance and its clinical effects in multidrug-resistant tuberculosis.
Cimen NO; Arslan Z; Saygi A; Ocak K; Babacan F; Kurutepe M
Int J Tuberc Lung Dis; 2009 Jul; 13(7):907-13. PubMed ID: 19555543
[TBL] [Abstract][Full Text] [Related]
29. Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
Choi J; Park SJ; Jee JG
Eur J Med Chem; 2015 Dec; 106():157-66. PubMed ID: 26544630
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results.
Singla R; Gupta S; Gupta R; Arora VK
Int J Tuberc Lung Dis; 2001 Jun; 5(6):559-63. PubMed ID: 11409584
[TBL] [Abstract][Full Text] [Related]
31. Drug-resistant tuberculosis: what do we do now?
Telenti A; Iseman M
Drugs; 2000 Feb; 59(2):171-9. PubMed ID: 10730543
[TBL] [Abstract][Full Text] [Related]
32. A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation.
Pastor A; Machelart A; Li X; Willand N; Baulard A; Brodin P; Gref R; Desmaële D
Org Biomol Chem; 2019 May; 17(20):5129-5137. PubMed ID: 31073555
[TBL] [Abstract][Full Text] [Related]
33. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations.
Machado D; Perdigão J; Ramos J; Couto I; Portugal I; Ritter C; Boettger EC; Viveiros M
J Antimicrob Chemother; 2013 Aug; 68(8):1728-32. PubMed ID: 23539241
[TBL] [Abstract][Full Text] [Related]
34. Reversion of antibiotic resistance in
Blondiaux N; Moune M; Desroses M; Frita R; Flipo M; Mathys V; Soetaert K; Kiass M; Delorme V; Djaout K; Trebosc V; Kemmer C; Wintjens R; Wohlkönig A; Antoine R; Huot L; Hot D; Coscolla M; Feldmann J; Gagneux S; Locht C; Brodin P; Gitzinger M; Déprez B; Willand N; Baulard AR
Science; 2017 Mar; 355(6330):1206-1211. PubMed ID: 28302858
[TBL] [Abstract][Full Text] [Related]
35. Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size.
de Steenwinkel JE; ten Kate MT; de Knegt GJ; Verbrugh HA; van Belkum A; Hernandez-Pando R; Bakker-Woudenberg IA
Int J Tuberc Lung Dis; 2011 Nov; 15(11):1478-84, i. PubMed ID: 22008760
[TBL] [Abstract][Full Text] [Related]
36. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
[TBL] [Abstract][Full Text] [Related]
37. Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of
de Welzen L; Eldholm V; Maharaj K; Manson AL; Earl AM; Pym AS
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993337
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
Prasad R; Verma SK; Sahai S; Kumar S; Jain A
Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
[TBL] [Abstract][Full Text] [Related]
39. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina.
Palmero DJ; Ambroggi M; Brea A; De Lucas M; Fulgenzi A; Martínez D; Mosca C; Musella R; Natiello M; Gonzalez C; Abbate E
Int J Tuberc Lung Dis; 2004 Jun; 8(6):778-84. PubMed ID: 15182150
[TBL] [Abstract][Full Text] [Related]
40. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
